These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30927979)

  • 1. Choosing induction chemotherapy in therapy-related acute myeloid leukemia.
    Shea LK; Uy GL
    Best Pract Res Clin Haematol; 2019 Mar; 32(1):89-97. PubMed ID: 30927979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML.
    Cheung E; Perissinotti AJ; Bixby DL; Burke PW; Pettit KM; Benitez LL; Brown J; Scappaticci GB; Marini BL
    Ann Hematol; 2019 Mar; 98(3):541-559. PubMed ID: 30666431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can one optimize induction therapy in AML?
    Luger SM
    Best Pract Res Clin Haematol; 2017 Dec; 30(4):301-305. PubMed ID: 29156199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CPX-351: changing the landscape of treatment for patients with secondary acute myeloid leukemia.
    Talati C; Lancet JE
    Future Oncol; 2018 May; 14(12):1147-1154. PubMed ID: 29378418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
    Lancet JE; Uy GL; Cortes JE; Newell LF; Lin TL; Ritchie EK; Stuart RK; Strickland SA; Hogge D; Solomon SR; Stone RM; Bixby DL; Kolitz JE; Schiller GJ; Wieduwilt MJ; Ryan DH; Hoering A; Banerjee K; Chiarella M; Louie AC; Medeiros BC
    J Clin Oncol; 2018 Sep; 36(26):2684-2692. PubMed ID: 30024784
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML.
    Cortes JE; Lin TL; Uy GL; Ryan RJ; Faderl S; Lancet JE
    J Hematol Oncol; 2021 Jul; 14(1):110. PubMed ID: 34256819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
    Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
    Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liposomal encapsulated cytarabine and daunorubicin (CPX-351) for older patients with acute myeloid leukemia.
    Asghari H; Lancet J
    Leuk Lymphoma; 2020 Jun; 61(6):1305-1312. PubMed ID: 32037927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options.
    Richardson DR; Green SD; Foster MC; Zeidner JF
    Curr Hematol Malig Rep; 2021 Feb; 16(1):97-111. PubMed ID: 33609248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
    Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
    Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?
    Tang K; Schuh AC; Yee KW
    Curr Oncol Rep; 2021 Aug; 23(10):120. PubMed ID: 34350512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health state utilities associated with treatment options for acute myeloid leukemia (AML).
    Matza LS; Deger KA; Howell TA; Koetter K; Yeager AM; Hogge D; Fisher V; Louie AC; Chung KC
    J Med Econ; 2019 Jun; 22(6):567-576. PubMed ID: 30775943
    [No Abstract]   [Full Text] [Related]  

  • 13. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is the overall survival for older adults with AML finally improving?
    Lancet JE
    Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are adjuncts to induction chemotherapy worthwhile in the treatment of acute myeloid leukemia?
    Ravandi F
    Best Pract Res Clin Haematol; 2014; 27(3-4):241-6. PubMed ID: 25455273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recently approved therapies in acute myeloid leukemia: A complex treatment landscape.
    Talati C; Sweet K
    Leuk Res; 2018 Oct; 73():58-66. PubMed ID: 30223250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daunorubicin-cytarabine liposome (CPX-351) in the management of newly diagnosed secondary AML: A new twist on an old cocktail.
    Maakaron JE; Mims AS
    Best Pract Res Clin Haematol; 2019 Jun; 32(2):127-133. PubMed ID: 31203994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AML with Myelodysplasia-Related Changes: Development, Challenges, and Treatment Advances.
    Koenig KL; Sahasrabudhe KD; Sigmund AM; Bhatnagar B
    Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32722092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
    Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
    J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.